Back to Resource Hub Article

Increasing the Usefulness of COAs in Heart Failure Research

Dr. Bill Byrom, Principal, eCOA Science at Signant Health, recently had the pleasure of sitting down with Professor Julian Gillmore, Professor of Medicine at University College London (UCL) and Honorary Consultant at Royal Free Hospital, and a member of the Signant Health Scientific Advisory Board.

They discussed current and future opportunities for increasing the usefulness of clinical outcome assessments (COAs) measures in heart failure clinical trials.

Read their conversation to find out more on developments in new treatments for amyloidosis and the limitation on 6MWT.

Similar posts

Looking for more insights? Explore related resources.

ARTICLE

Conversation with Bill Byrom & Mariana Fontana: Measuring Aspects of Health in Heart Failure Research

READ THE ARTICLE
BROCHURE

Signant Health Corporate Overview

SEE THE BROCHURE
SOLUTION

Congestive Heart Failure (CHF) Trial Solutions

VISIT THE PAGE

Get notified on new marketing insights

Here mention the benefits of subscribing